<p>ChinaAMC (Hong Kong) partners with Franklin Templeton to launch two new ETFs, building an investment bridge connecting China and global markets</p>

• ChinaAMC and Franklin Templeton have partnered to launch two new ETFs in the Hong Kong market.
• This product launch marks the first collaboration under their strategic partnership framework.
• The two ETFs employ differentiated strategies: one focuses on listed companies with strong cash flow performance in Hong Kong and U.S. markets; the other targets innovative pharmaceutical firms driven by R&D in developed markets globally and in Hong Kong.
• The two ETFs were officially listed on the Hong Kong Stock Exchange on September 29, with trading counters available in HKD, USD, and CNY.

[Hong Kong, September 29, 2026]

ChinaAMC Limited (“ChinaAMC”) is pleased to announce that the ChinaAMC Franklin FTSE China A-Shares Cash Flow Focus ETF and the ChinaAMC Franklin FTSE Innovative Medicines ETF (collectively, the “Funds”) successfully listed today on The Stock Exchange of Hong Kong (the “HKEX”). Jointly developed by ChinaAMC and Franklin Templeton and issued and managed by ChinaAMC, these new products not only broaden investors’ options for cross-market asset allocation but also further solidify Hong Kong’s position as a hub connecting Chinese and global capital markets.

This listing represents a milestone product achievement within the broad strategic cooperation framework between ChinaAMC’s parent company, China Asset Management Co., Ltd. (“ChinaAMC”), and Franklin Templeton, focusing on investment themes across China, the U.S., and global markets. Combining ChinaAMC’s mature ETF platform and product development capabilities with Franklin Templeton’s expertise and research platform in the global ETF space, the two Funds target two complementary investment themes: companies demonstrating resilience and superior cash generation capabilities amid market uncertainty, and R&D-driven innovative pharmaceutical enterprises at the forefront of healthcare.

ChinaAMC Franklin FTSE China A-Shares Cash Flow Focus ETF

This fund aims to provide investors with resilient and high-quality investment targets by tracking the Solactive G2 Cash Flow Index NTR. The index covers 20 securities listed in Hong Kong eligible for Stock Connect and 80 securities listed in the United States, with target weights of 60% and 40% for Hong Kong and U.S. markets, respectively. To be included, issuers must have generated positive operating cash flow in each of the past three fiscal years and meet screening criteria for expected positive free cash flow; financial sector companies are excluded. Using a unified cash flow screening framework across both markets, the index systematically identifies companies with core businesses capable of funding reinvestment and shareholder returns. Based on this stock-picking logic, the fund aims to create a defensive allocation tool centered on cash flow strength for investors seeking exposure to Hong Kong and U.S. equities.

ChinaAMC Franklin FTSE Innovative Medicines ETF

ChinaAMC Franklin FTSE Innovative Medicines ETF: This fund tracks the FTSE ETF Passages Innovative Medicines Index (Net Total Return Version), aiming to offer a growth-oriented investment strategy. The index includes 30 Hong Kong-listed securities eligible for Stock Connect and 70 developed market securities, with target weights of 65% and 35% for Hong Kong and developed markets, respectively. The index focuses on pharmaceutical and biotech companies with strong R&D capabilities, excludes traditional Chinese medicine firms and medical outsourcing service providers, and periodically adjusts component weights based on R&D intensity. By linking high-quality innovative pharmaceutical companies in China and globally, the fund captures cross-border drug development trends, providing investors with exposure to the forefront of global healthcare innovation and companies with long-term capital appreciation potential.

Gan Tian, CEO of ChinaAMC stated:

“In a global market environment characterized by rising cost of capital, accelerated innovation, and divergent growth, demand for diversified investment strategies continues to rise. The newly launched products adopt two complementary strategies, presenting investors with two long-value investment themes: companies with robust and sustained cash generation capabilities, and R&D-driven innovative pharmaceutical tracks. The joint development of these products fully demonstrates the deep collaboration between ChinaAMC and Franklin Templeton around global cross-border investment themes. We look forward to connecting Hong Kong with the U.S. and other developed markets through these two new investment tools, helping investors achieve diversified cross-market allocation and seize long-term structural opportunities.”

Rene Buehlmann, President of Asia Pacific at Franklin Templeton stated:

“We are very excited to partner with ChinaAMC to launch these milestone ETFs, which are among the first ETFs listed by Franklin Templeton in Asia. Leveraging ChinaAMC’s solid ETF management capabilities and Franklin Templeton’s global investment strength, we bring attractive long-term investment themes to investors. This milestone also confirms our firm commitment to deepening our presence in the regional ETF market, enriching client investment choices, and dedicated to creating global cross-market, differentiated investment opportunities for investors.”

Product Details:

About ChinaAMC (Hong Kong)

ChinaAMC is a leading asset management company in the Hong Kong market. As the overseas subsidiary of ChinaAMC, it was established in Hong Kong in 2008, being one of the first mainland Chinese asset management firms to expand overseas. Its parent company, ChinaAMC, is one of the largest fund companies in China and the largest ETF manager in the country. As of December 31, 2025, its total assets under management exceeded $464.5 billion.

Rooted in Hong Kong with a global outlook, after 17 years of development, ChinaAMC has accumulated excellent performance in both active and passive investment areas. The company possesses deep professional expertise in diversified assets, with business scope covering equities, fixed income, ETFs, leveraged and inverse products, digital assets, as well as discretionary account management and investment advisory services.

In the field of passive investment and ETFs, ChinaAMC is one of the most active issuers in the Hong Kong market. Our global ETF product line is broadly distributed, covering Greater China, Asia-Pacific, Europe, and the U.S., with asset classes spanning equities, fixed income, and digital assets. With such extensive geographic and asset coverage, ChinaAMC offers the most comprehensive product series among all ETF issuers in Hong Kong.

About Franklin Templeton’s ETF Business

Franklin Templeton’s global ETF platform provides investors with a wide range of index-based and actively managed ETF solutions, aimed at helping achieve diversified investment goals. Supported by the strength and resources of one of the world’s largest asset managers, the platform’s global assets under management were approximately $83 billion as of August 31, 2026.

About Franklin Templeton

Franklin Templeton is a trusted investment partner committed to providing customized investment solutions aligned with clients’ strategic objectives. Combining exceptional investment capabilities with cutting-edge technology, backed by deep investment management experience across public and private markets. Since its establishment in 1947, we have empowered clients to seize market opportunities and navigate changes calmly through strategic partnerships, forward-looking insights, and continuous innovation.

As of August 31, 2026, Franklin Templeton’s assets under management were approximately $1.83 trillion, with operations in over 35 countries and regions worldwide.

Contact and Inquiries

General inquiries: hkservice@chinaamc.com.hk

Media inquiries: pr_events@chinaamc.com.hk

Copyright © 2026 Franklin Templeton.

Franklin Templeton Investments (Asia) Limited is the issuer of this document. This document does not constitute an offer or solicitation to purchase fund shares. Investment involves risk. Fund values may fluctuate, and past performance is neither an indicator nor a guarantee of future results. For further information regarding any funds mentioned in this document (including risk factors), please refer to the relevant offering documents. This document has not been reviewed by the Securities and Futures Commission of Hong Kong.

Funds are traded on the exchange at prevailing market prices, which may differ from their corresponding net asset values.

Copyright © 2026 ChinaAMC (Hong Kong) Limited.

Investment involves risks, including possible loss of principal. Past performance does not indicate future fund returns. This document is for your reference only and does not constitute an invitation or offer to buy or sell any securities or funds, nor does it constitute any investment advice. It was not prepared for any such invitation or offer. The issuer of this material is ChinaAMC (Hong Kong) Limited. This material has not been reviewed by the Securities and Futures Commission of Hong Kong.

Data Source: ChinaAMC (Hong Kong), data as of September 29, 2026.https://www.chinaamc.com.hk/?lan=EN

$PETROCHINA(00857.HK) $CNOOC(00883.HK)$COSCO SHIP HOLD(01919.HK) $MEITUAN(03690.HK) $KEYMED BIO-B(02162.HK) $JUNSHI BIO(01877.HK) $BEONE MEDICINES(06160.HK) $AKESO(09926.HK) $SKB BIO(06990.HK) $INNOCARE(09969.HK)